FMD |。 How long can immunity last after a new coronavirus infection?

Title: Durability of neutralizing antibodies and T-cell response post SARS-CoV-2 infected
Journal:
Yun Tan, Feng Liu, Xiaoguang Xu, Yun Ling, Weijin Huang, Zhaoqin Zhu, Mingquan Guo, Yixiao Lin, Ziyu Fu, Dongguo Liang, Tengfei Zhang, Jian Fan, Miao Xu, Hongzhou Lu, Saijuan Chen
Published: 30 September 2020
DOI:
WeChat Link:
According to the World Health Organization, as of September 29, 2020, there are 33,249,563 worldwide The number of confirmed cases of neo-crown pneumonia has reached 1,000,040. Studies have shown that the body can produce antibodies and T-cells that respond to the new coronavirus after infection, but it is not clear how long these immunitys will last, and the results of different teams are inconsistent. A team of researchers detected dynamic changes in new coronavirus antibodies a month after the new coronavirus infection, and found that after one month, the number of antibodies in patients with mild and severe infections decreased, suggesting that antibody immune life against coronavirus may be short. Another study looked at antibody levels in patients four months after a new coronavirus infection, and found that new coronavirus-specific antibodies rose rapidly after infection and remained at relatively stable levels for four months. However, the emergence of a second case of viral infection after the first virus infection has been cured has heightened doubts about post-infection immunity and the ability of vaccines to prevent new coronavirus infections.
In order to determine whether antibodies can exist in the human body for a long time after the new coronavirus infection, the National Translational Medical Center of Ruijin Hospital, Shanghai Hematology Research Institute, National Key Laboratory of Medical Genomics, Shanghai Public Health Clinical Center and China Food and Drug Inspection Research Institute have carried out long-term monitoring of new crown infection. The researchers analyzed the expression levels of IgG antibodies in plasma samples from patients 2 weeks to 1 month, 1-2 months and 6-7 months after infection, and found that in plasma samples infected for 6-7 months, anti-neo-coronavirus IgG antibodies decreased from 2 weeks to 1 month and 1-2 months after infection, but remained at a high level. The researchers further analyzed the levels of new coronavirus and antibodies in plasma samples 2 weeks to 2 months and 6-7 months after infection, and found that there were highly active neo-coronavirus mesoth antibodies in all samples, and there was no difference in the level of meso antibodies in plasma samples from 2 weeks to 2 months and 6-7 months. This result shows that protective neutral antibodies are still present in the human body six months after the new coronavirus infection. The researchers also analyzed the presence of memory T cells for the new coronavirus in the blood of those who recovered after 6-7 months of infection and found that CD4 and CD8 T cells that responded to the new coronary antigen were present in all test samples.
the virus that caused this year's new crown outbreak is the 614D new coronavirus, but the recent emergence of 614G mutant strains makes the new coronavirus more contagious. Whether human infection with the 614G variant virus can produce sufficient protection has become a high-profile issue. The current vaccines against the new coronavirus are based on the 614D virus, and it is also worrying whether these vaccines can protect the human body from 614G virus infection. To answer these questions, the researchers further analyzed the ability of antibodies taken from plasma samples to mediat 614G analog viruses, or fake viruses. They found that although most patients were infected with the 614D new coronavirus six months ago, their plasma samples had the same ability to median the 614D and 614G new coronavirus, suggesting that those infected with the 614D virus were also immune to the 614G virus, and speculated that the new coronavirus based on 614D should be trustworthy.The study was published in
(link:
), and the co-authors are Dr. Tan Yun, Dr. Tan Yun, Dr. Liu Feng, Dr. Xu Xiaoguang, Dr. Ling Yun, Dr. Zhu Zhaoqin, Dr. Guo Mingquan, Dr. Lin Yixuan and Huang Weijin of the National Key Laboratory of Medical Genomics, affiliated with Shanghai Jiaoda University School of Medicine. The co-authors are Professor Chen Saiju
of the National Translational Medicine Center of Ruijin Hospital, Shanghai Hematology Research Institute, National Key Laboratory of Medical Genomics, and Lu Hongzhou, Shanghai Public Health Clinical Center, affiliated with Shanghai Jiaoxuan University School of Medicine.is one of
series of English academic journals published overseas by the Head of the Ministry of Education, the Higher Education Press and the German company Springer, published in both online and print editions, and was launched in January 2007 in a bi-monthly edition. The editor-in-chief of this newspaper is
Professor Chen Saixuan of the Shanghai Institute of Hematology of Ruijin Hospital, affiliated with Shanghai Jiaotong University School of Medicine, Professor Zhang Baili of the Chinese Academy of Engineering
, Tianjin University of Traditional Chinese Medicine, Professor Yang Baofeng of the Chinese Academy of Engineering
, Professor Yang Baofeng of Harbin Medical University,
Professor Chen Xiaoping of the Department of External Sciences of Tongji Hospital, Tongji University of Science and Technology, China University of Science and Technology. This is a comprehensive academic journal of English medicine, reporting areas such as clinical medicine, basic medicine, translational medicine, epidemiology, Chinese medicine, public health, health policy, etc., in the types of articles edited by Editorial (editorial), News and Views (NewsView), Reviews (review), Mini-review Research Articles (Original Research Papers), Case Report (Case Report), Commentary (Comment), Letter to Frontiers of Medicine


(Source: Science.com)